- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03099122
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant (START-DCD)
A Prospective, Multi-center, Single-arm, Interventional Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant in China
Primary Objective:
To investigate the efficacy of the standard dose of Thymoglobuline® induction therapy for preventing acute rejection (AR) after transplantation among recipients of Donated after Cardiac Death (DCD) kidney transplant.
Secondary Objectives:
- To evaluate delayed graft function (DGF), graft and patient survival after kidney transplant.
- To evaluate adverse events of Thymoglobuline® throughout the study.
- To explore possible risk factors of AR and DGF in patients with DCD kidney transplant.
- To evaluate AR and DGF under different risk stratifications and explore an description optimal induction therapy regimen for recipients of DCD kidney transplant.
Visão geral do estudo
Status
Condições
Descrição detalhada
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
-
China, China
- China
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria :
- Male or female.
- Patient is a Chinese recipient of kidney transplant for the first time.
- Patient is a recipient of kidney allograft from Chinese donors donated after cardiac death (including kidney donated after brain death followed by circulatory death).
- Recipient's age is between 18 to 65 years old (including 18 years).
- Donor's age is more than 5 years old.
- Recipient's weight is greater than or equal to 50 kg but less than or equal to 80 kg.
- Patient fully understands the study and signs the informed consent form (ICF) prior to any study procedure.
Exclusion criteria:
- Patient is a multiple organ transplant recipient.
- Recipient with previous kidney or other organ transplant history.
- Recipient and donor have incompatible blood types.
- Recipient and donor have 5 or 6 mismatched human leucocyte antigen (HLA).
- Recipient is known to have an active infection or active chronic infection, or is seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV Ab), or human immunodeficiency virus (HIV). (Serological test results within 12 months before transplantation are acceptable.)
- Recipient with cytomegalovirus (CMV) immunoglobulin G (IgG) negative who receives an allograft from CMV IgG positive donor (CMV IgG [D+/R-]).
- Any systemic infection requiring continuous treatment at enrolment, but prophylactic treatment of CMV and/or Pneumocystis carinii pneumonia (PCP) is allowed.
- Recipient has severe thrombocytopenia or leucopenia before operation (platelet count <75,000/ul, or the number of white blood cells <3,000 cells/mm3).
- Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma glutamine transferase (GGT) ≥3ULN (upper limit of normal) within 1 week before transplantation, and not normalized at time of transplantation.
- Recipient has a history of malignancy within 5 years.
- Recipient with history of allergy and anaphylaxes to rabbit proteins or to any excipients.
- Recipient has known contraindications to the administration of Thymoglobuline®.
- Recipient has taken other investigational drugs or prohibited therapy for this study within 1 month or 5 of half-lives from screening, whichever is longer.
- Recipient has previously used Thymoglobuline®, or has participated in any clinical trial of any other medicine or device within 30 days before signing ICF.
- Pregnant or lactating women.
- Male and female patients do not agree to practice medically acceptable contraception (i.e., barrier or pharmacologic: male patient must use condoms or his female partner must take oral contraceptives; the male partner of a female patient must use condoms ) for at least 6 months following the study treatment.
Conditions/situations such as:
- Recipient not suitable for participation, whatever the reason, as judged by the Investigator, including medical, clinical, or psychosocial conditions, or patient potentially at risk of noncompliance to study procedures.
- Donor known or suspected to have active infection before donation (such as blood cultures positive, seropositive for hepatitis B surface antigen [HBsAg], or antibody against hepatitis C virus [HCVAb], or human immunodeficiency virus [HIV]) or hypersensitive recipients (eg, panel reactive antibody [PRA] positive) before transplantation, judged by the Investigator.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Thymoglobuline
A cumulative dose of Thymoglobuline will be given intravenously, with a variable interval dose. Methylprednisolone will be given as induction therapy, according to institutional practice. Tacrolimus, mycophenolate, and prednisone will be given as maintenance therapies. |
Pharmaceutical form: creamy-white powder Route of administration: intravenous
Outros nomes:
Pharmaceutical form: tablet Route of administration: oral Pharmaceutical form: powder Route of administration: intravenous Pharmaceutical form: capsule Route of administration: oral Pharmaceutical form: capsule Route of administration: oral Pharmaceutical form: tablet Route of administration: oral |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Percentage of patients with biopsy-proven acute rejection events
Prazo: 6 months
|
6 months
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Percentage of delayed graft function events
Prazo: 6 months
|
6 months
|
Duration of delayed graft function events
Prazo: 6 months
|
6 months
|
Percentage of survived grafts
Prazo: 6 months
|
6 months
|
Percentage of survived patients
Prazo: 6 months
|
6 months
|
Assessment of acute rejection risk factors
Prazo: 6 months
|
6 months
|
Assessment of delayed graft function risk factors
Prazo: 6 months
|
6 months
|
Percentage of acute rejection events in different risk stratifications
Prazo: 6 months
|
6 months
|
Percentage of delayed graft function events in different risk stratifications
Prazo: 6 months
|
6 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças renais
- Doenças Urológicas
- Insuficiência renal
- Insuficiência Renal Crônica
- Morte
- Insuficiência Renal Crônica
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Agentes Autônomos
- Agentes do Sistema Nervoso Periférico
- Inibidores Enzimáticos
- Antiinflamatórios
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Antieméticos
- Agentes gastrointestinais
- Glicocorticóides
- Hormônios
- Hormônios, Substitutos Hormonais e Antagonistas Hormonais
- Agentes Antineoplásicos Hormonais
- Agentes Neuroprotetores
- Agentes de proteção
- Agentes antibacterianos
- Antibióticos, Antineoplásicos
- Agentes Antituberculares
- Antibióticos, Antituberculose
- Inibidores de Calcineurina
- Metilprednisolona
- Imunoglobulinas
- Prednisona
- Tacrolimo
- Ácido micofenólico
- Timoglobulina
- Soro Antilinfócito
Outros números de identificação do estudo
- THYMOL07282
- U1111-1178-5402 (Outro identificador: UTN)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .